The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.

The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.

The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.

By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of a proteinuric kidney disease with voclosporin can be maximized while minimizing undesirable side effects.

By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of a proteinuric kidney disease with voclosporin can be maximized while minimizing undesirable side effects.

Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.

Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.

Methods for treating an inflammatory bowel disease or at least one symptom thereof, comprising administering to a subject in need thereof an effective amount of: a compound selected from an immunosuppressant and an aminosalicylate; and one or more Lactobacillus species selected from Lactobacillus buchneri, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus rapi, Lactobacillus parafarraginis, and Lactobacillus diolivorans, and/or a culture supernatant or cell free culture filtrate derived from culture media in which said one or more Lactobacillus species has been cultured.

Methods for treating an inflammatory bowel disease or at least one symptom thereof, comprising administering to a subject in need thereof an effective amount of: a compound selected from an immunosuppressant and an aminosalicylate; and one or more Lactobacillus species selected from Lactobacillus buchneri, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus rapi, Lactobacillus parafarraginis, and Lactobacillus diolivorans, and/or a culture supernatant or cell free culture filtrate derived from culture media in which said one or more Lactobacillus species has been cultured.

Methods for treating an inflammatory bowel disease or at least one symptom thereof, comprising administering to a subject in need thereof an effective amount of: a compound selected from an immunosuppressant and an aminosalicylate; and one or more Lactobacillus species selected from Lactobacillus buchneri, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus rapi, Lactobacillus parafarraginis, and Lactobacillus diolivorans, and/or a culture supernatant or cell free culture filtrate derived from culture media in which said one or more Lactobacillus species has been cultured.